RT Journal Article
T1 Characterization and Therapeutic Effect of a pH Stimuli Responsive Polymeric Nanoformulation for Controlled Drug Release
A1 Cano-Cortes, Maria Victoria
A1 Laz-Ruiz, Jose Antonio
A1 Diaz-Mochon, Juan Jose
A1 Sanchez-Martin, Rosario Maria
K1 Covalent drug conjugation
K1 Therapeutic nanodevice
K1 Polymeric nanoparticles
K1 Cancer therapy
K1 Controlled drug deliver
K1 Concentración 50 Inhibidora
K1 Nanopartículas
K1 Concentración de iones de hidrógeno
AB Despite the large number of polymeric nanodelivery systems that have been recently developed, there is still room for improvement in terms of therapeutic efficiency. Most reported nanodevices for controlled release are based on drug encapsulation, which can lead to undesired drug leakage with a consequent reduction in efficacy and an increase in systemic toxicity. Herein, we present a strategy for covalent drug conjugation to the nanodevice to overcome this drawback. In particular, we characterize and evaluate an effective therapeutic polymeric PEGylated nanosystem for controlled pH-sensitive drug release on a breast cancer (MDA-MB-231) and two lung cancer (A549 and H520) cell lines. A significant reduction in the required drug dose to reach its half maximal inhibitory concentration (IC50 value) was achieved by conjugation of the drug to the nanoparticles, which leads to an improvement in the therapeutic index by increasing the efficiency. The genotoxic effect of this nanodevice in cancer cells was confirmed by nucleus histone H2AX specific immunostaining. In summary, we successfully characterized and validated a pH responsive therapeutic polymeric nanodevice in vitro for controlled anticancer drug release.
PB MDPI
YR 2020
FD 2020-06-01
LK http://hdl.handle.net/10668/3515
UL http://hdl.handle.net/10668/3515
LA en
NO Cano-Cortes MV, Laz-Ruiz JA, Diaz-Mochon JJ, Sanchez-Martin RM. Characterization and Therapeutic Effect of a pH Stimuli Responsive Polymeric Nanoformulation for Controlled Drug Release. Polymers. 2020 Jun 1;12(6):1265
DS RISalud
RD Apr 8, 2025